PA5-103522

antibody from Invitrogen Antibodies

Targeting: MRPL2 CGI-22, MRP-L14, RPML14

Western blot (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-103522

Provider

Invitrogen Antibodies

Product name

MRPL2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Antibody detects endogenous levels of total MRPL2.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

-20°C

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of MRPL2 in mouse lung tissue lysate (left lane: treated with blocking peptide). Samples were incubated with MRPL2 polyclonal antibody (Product # PA5-103522).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of MRPL2 in HUVEC cell lysate. Samples were incubated with MRPL2 polyclonal antibody (Product # PA5-103522).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of MRPL2 in mouse lung tissue lysate (left lane: treated with blocking peptide). Samples were incubated with MRPL2 polyclonal antibody (Product # PA5-103522).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of MRPL2 in various samples (Lane 1: 293 cells treated with the blocking peptideLane 2: 293 cellsLane 3: rat lung tissueLane 4: mouse heart tissueLane 5: HeLa cells). Samples were incubated with MRPL2 polyclonal antibody (Product # PA5-103522).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of MRPL2 in various samples (Lane 1: mouse Myeloma cell treated with blocking peptide Lane 2: mouse Myeloma cell Lane 3: HeLa Lane 4: 293 Lane 5: HUVEC). Samples were incubated with MRPL2 polyclonal antibody (Product # PA5-103522).